Consistent with these findings, knockout of cGAS-STING pathway downstream targets or pharmacological targeting of Ik-kinase alpha (IKKa) may improve glucose tolerance and insulin sensitivity in patients with T2DM (47, 48). Here, STING1 is linked to type 2 diabetes mellitus.